ApoCIII-Induced CaV1 Channel Hyperactivation in Beta Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Elevated apolipoprotein CIII levels lead to hyperactivation of β cell CaV channels, contributing to β cell malfunction and death, particularly in diabetes mellitus, by increasing calcium influx, which is not effectively addressed by existing technologies.
Innovation Solution
Identifying candidate compounds that inhibit the ApoCIII-induced increase in CaV1 channel density and conductivity in insulin-secreting cells, using methods that involve contacting cells with ApoCIII in the presence of test compounds and evaluating their ability to inhibit these effects, with potential treatments including inhibitors of PKA, Src kinase, β1 integrin, and channel blockers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ApoCIII levels are elevated, then CaV channel density and conductivity increase, but this leads to calcium overload and beta cell death
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to block the interaction between ApoCIII and CaV1 channels. These compounds bind to CaV1 channels and prevent ApoCIII-induced hyperactivation, thereby reducing calcium overload while maintaining normal channel function. This mediator approach selectively counteracts the harmful effect without completely blocking calcium signaling.
Solution Approach 2:
The patent converts the harmful hyperactivation of CaV channels by ApoCIII into a beneficial therapeutic effect by using the same ApoCIII-CaV1 interaction pathway as a target. By designing compounds that specifically inhibit this pathological interaction, the harmful calcium overload is converted into a controlled reduction of calcium influx, protecting beta cells while preserving necessary calcium signaling for insulin secretion.
2Reliability
If CaV1 channel blockers are used to reduce calcium influx, then beta cell death is prevented, but insulin secretion may be impaired
Solution Approach 1:
The patent applies local quality by creating a state where CaV1 channels have different functional properties in different contexts. In the presence of ApoCIII, the channels are hyperactivated and harmful; in the absence of ApoCIII or with compound treatment, normal channel function is preserved. The small molecule compounds selectively modulate channel behavior only when ApoCIII is bound, allowing normal insulin secretion while blocking pathological calcium overload.
Solution Approach 2:
The patent introduces dynamics by using compounds that can reversibly bind to CaV1 channels and modulate their activity based on ApoCIII presence. The compounds do not permanently block channels but dynamically regulate calcium influx in response to ApoCIII levels, allowing the system to adapt and maintain insulin secretion while preventing beta cell death during acute stress.
3Object-affected harmful factors
If existing CaV channel blockers are used, then calcium influx is reduced, but they do not specifically address ApoCIII-induced hyperactivation
Solution Approach 1:
The patent employs small molecule compounds as intermediaries that specifically target the ApoCIII-CaV1 channel interaction. These compounds bind to CaV1 channels and prevent ApoCIII from inducing hyperactivation, providing selective inhibition of the pathological pathway while preserving normal channel function and insulin secretion mechanisms.
Solution Approach 2:
The patent changes the parameter of channel sensitivity to ApoCIII by using small molecule compounds that alter the binding affinity or conformational state of CaV1 channels. This parameter change makes the channels resistant to ApoCIII-induced hyperactivation while maintaining their ability to respond to physiological signals for insulin secretion.
Data Source
AI summary
The present invention provides methods for identifying candidate compounds for limiting development of and/or treating diabetes, and methods for limiting development of and/or treating diabetes.